Fol. Biol. 2003, 49, 26-32
https://doi.org/10.14712/fb2003049010026
Local IFN-γ Therapy of HPV16-Associated Tumours
References
1. , A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, K. H., Reaman, G. H., Tosato, G. (1995) Human interferon-inducible protein 10 is a potent inducer of angiogenesis in vivo. J. Exp. Med. 182, 155-162.
<https://doi.org/10.1084/jem.182.1.155>
2. , M. J., Luistro, L., Hendrzack, J. A., Fountolakis, M., Garotta, G., Gateley, M. K. (1995) Role of IFN-γ in mediating the antitumor efficacy of IL-12. J. Immunother. 17, 71-77.
<https://doi.org/10.1097/00002371-199502000-00001>
3. , J., Šímová, J., Hájková R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková, E., Vonka, V. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV16. Int. J. Oncol. 14, 593-597.
4. Bubeník, J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Indrová, M. (2002) Interleukin 2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine, in press.
5. , M. E., Stern, P. L. (1990) Loss of MHC class I expression in cervical carcinomas. Int. J. Cancer 46, 1029-1034.
<https://doi.org/10.1002/ijc.2910460614>
6. , F., Ruiz-Cabello, F., Cabrera, I., Perez-Villaz, J. J., Lopez-Botet, M., Duggan-Keen, M., Stern, P. L. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95.
<https://doi.org/10.1016/S0167-5699(96)10075-X>
7. , D. J., Marincola, F. M., Ferrone, S. (1999) HLA class I antigen downregulation in human cancers: T cell immunotherapy revives an old story. Mol. Med. Today 5, 178-186.
<https://doi.org/10.1016/S1357-4310(99)01451-3>
8. , M., Bubeník, J., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyšková, R. (2001) Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep. 8, 1371-1374.
9. , M., Bubeník, J., Mikyšková, R., Vonka, V., Šmahel, M., Žák, R., Šímová, J., Bieblová, J., Mendoza, L., Jandlová, T. (2002) Tumour-inhibitory and antimetastatic effect of IL-2 in mice carrying MHC class Itumours of HPV16 origin. Int. J. Oncol. 20, 643-646.
10. Indrová, M., Bubeník, J., Mikyšková, R., Mendoza, L., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Pajtasz-Piasecka E. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class Itumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines, Int. J. Oncol., in press.
11. , R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Jandlová, T. (2001) Local cytokine treatment of HPV16-associated tumours results in inhibition of the lung metastases. Clin. Exp. Metastasis 18, 581-587.
<https://doi.org/10.1023/A:1011987206008>
12. , J. G., Lee N. C., Tsung Y. L., Norton J. A., Tsung K. (2002) The role of IFN-γ in rejection of established tumors by IL-12: source of production and target. Cancer Res. 62, 4696-4703.
13. , M., Cavallo, F., Geuna, M., Mitola, S., Colombo, M. P., Forni, G., Bussolino, F. (2001) IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 166, 3890-3899.
<https://doi.org/10.4049/jimmunol.166.6.3890>
14. , M., Sobotková, E., Bubeník, J., Šímová, J., Žák, R., Ludvíková, V., Hájková R, Kovařík, J., Jelínek, F., Povýšil, C., Marinov, J., Vonka, V. (2001) Metastatic MHC class I- negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84, 374-380.
<https://doi.org/10.1054/bjoc.2000.1615>
15. Šmahel, M., Šíma, P., Ludvíková, V., Marinov, I., Pokorná, D., Vonka, V. Immunization with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine, in press.
16. , V., Rössner, P., Indrová, M., Bubeník, J., Sobota, V. (1998) Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer 76, 115-119.
<https://doi.org/10.1002/(SICI)1097-0215(19980330)76:1<115::AID-IJC18>3.0.CO;2-B>
